Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight (Q37931083)

25 August 2017

1 reference

title

Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight (English)

1 reference

interstitial lung disease

25 August 2017

1 reference

1 reference

Ji Hye Min

1

1 reference

25 August 2017

Ho Yun Lee

2

1 reference

25 August 2017

Hoyeong Lim

3

1 reference

25 August 2017

Myung-Ju Ahn

4

1 reference

25 August 2017

Keunchil Park

5

1 reference

25 August 2017

Man Pyo Chung

6

1 reference

25 August 2017

Kyung Soo Lee

7

1 reference

25 August 2017

13 September 2011

1 reference

Cancer Chemotherapy and Pharmacology

25 August 2017

1 reference

25 August 2017

68

1 reference

25 August 2017

5

1 reference

25 August 2017

1099-1109

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1737-2

25 August 2017

0 references

cites work

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Interstitial lung disease associated to erlotinib treatment: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Pulmonary complications of novel antineoplastic agents for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Interstitial lung disease associated with drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Diagnosis and management of drug-associated interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

FDA drug approval summary: erlotinib (Tarceva) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Targeted therapies for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Targeting angiogenesis in the treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Alveolitis: the key to the interstitial lung disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Understanding the mechanisms of drug-associated interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Distribution of epidermal growth factor and epidermal growth factor receptor in human lung: immunohistochemical and immunoelectron-microscopic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Chemotherapy-induced pulmonary toxicity in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Pulmonary drug toxicity: radiologic and pathologic manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Fleischner Society: glossary of terms for thoracic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Idiopathic interstitial pneumonias: CT features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

21 January 2018

Bronchiolar disorders.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Bronchiolitis: the pathologist's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Drug-associated organizing pneumonia: high-resolution CT findings in 9 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Severe interstitial lung disease associated with amrubicin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1737-2

10.1007/S00280-011-1737-2

21 January 2018

Identifiers

DOI

1 reference

release_m7ab5i3r5vcabik6imf2n2ypty

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m7ab5i3r5vcabik6imf2n2ypty

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference